country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-187427

Copy Link Print Information

LMed 93

LMed 93 is an antiviral agent. LMed 93 inhibits the activity of influenza A virus RNA polymerase. LMed 93 suppresses viral RNA synthesis. LMed 93 inhibits the replication of influenza A viruses H5N1 and H1N1. LMed 93 can be used for the research of influenza A virus infections (H1N1, H5N1).

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

화학식: C₁₉H₁₃ClO₅
분자량:356.76

보관:

Please store the product under the recommended conditions in the Certificate of Analysis.

LMed 93 Chemical Structure

Amount: USD 0.00

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- 제품 설명
- IC₅₀ & Target
- Cellular Effect
- In Vitro
Chemical Information
Protocol (1)
순도&문서
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

제품 설명

IC₅₀ & Target

^[1]

RNA Polymerase

All DNA/RNA Synthesis Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
MDCK-II	EC50	5.66 μM	Inhibition of Influenza A virus H1N1 (A/WSN/1933) replication in MDCK II cells assessed via Focus Forming Assay after 24 h incubation with simultaneous virus inoculation and reagent treatment. Inhibition of Influenza A virus H1N1 (A/WSN/1933) replication in MDCK II cells assessed via Focus Forming Assay after 24 h incubation with simultaneous virus inoculation and reagent treatment.	42485991
MDCK-II	EC50	9.13 μM	Inhibition of Influenza A virus H5N1 (A/Thailand/KAN-1/2004) replication in MDCK II cells assessed via Focus Forming Assay after 24 h incubation with simultaneous virus inoculation and reagent treatment. Inhibition of Influenza A virus H5N1 (A/Thailand/KAN-1/2004) replication in MDCK II cells assessed via Focus Forming Assay after 24 h incubation with simultaneous virus inoculation and reagent treatment.	42485991

In Vitro

LMed 93 (0.4-350 μM; 24 h) potently inhibits Influenza A virus H1N1 replication in MDCK II cells with an EC₅₀ of 5.66 μM and a high selectivity index of >49.52^[1].
LMed 93 (4.375-70 μM) inhibits Influenza A virus H5N1 replication in MDCK II cells with an EC₅₀ of 9.13 μM and a high selectivity index of >30.71^[1].
LMed 93 (70 μM) potently inhibits Influenza A virus H1N1 replication in MDCK II cells during early and intermediate infection stages (1 hpi and 3 hpi) but has reduced efficacy at late stages (6 hpi)^[1].
LMed 93 (70 μM) significantly reduces viral genomic RNA (vRNA) levels in H1N1-infected MDCK II cells at all post-infection time points tested, without altering viral mRNA levels^[1].
LMed 93 (35-70 μM; 20 h) modestly inhibits Influenza A virus RNA polymerase activity in MDCK II cells, reducing reporter activity by 38.7% at 35 μM and 53.7% at 70 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Real Time qPCR^[1]

View Protocol

Cell Line:

MDCK II cells
Concentration:

70 μM
Incubation Time:

8 h (1 hpi to 9 hpi); 6 h (3 hpi to 9 hpi); 3 h (6 hpi to 9 hpi)
Result:

Reduced M1 vRNA levels by 82% (n-fold = 0.18) at 1 hpi.
Reduced M1 vRNA levels by 78% (n-fold = 0.22) at 3 hpi.
Reduced M1 vRNA levels by 60% (n-fold = 0.40) at 6 hpi.
Did not significantly reduce M1 or PB1 mRNA levels at any time point.

Chemical Information

분자량 356.76
화학식 C₁₉H₁₃ClO₅
SMILES

ClC1=CC=C(OC(C(C(/C=C/C2=CC(OC)=C(O)C=C2)=O)=C3)=O)C3=C1
선적

Room temperature in continental US; may vary elsewhere.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.

Protocol

All Signal Pathway Related

Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.

순도&문서

Handling Instructions (2659 KB)

References

[1]. Darido MLG, et al. Integrated in silico and in vitro approaches reveal novel coumarin hybrids targeting influenza A virus RNA-dependent RNA polymerase. European journal of medicinal chemistry. 2026 Jul 19;318:119172.

Calculators

몰농도 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

농도 희석 계산기

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

견적 받기 해외재고보유

Other size

견적 받기